SparingVision appoints Anjeza Gjino as Chief Financial Officer
Paris, 3 March, 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, announces the appointment of Anjeza Gjino as Chief Financial Officer (CFO), having previously served as interim CFO for the Company since July 2024.
Prior to joining SparingVision, Anjeza served as CFO and Corporate Secretary at Cyclerion Therapeutics, where she played a key role in the company’s launch and public listing on Nasdaq in 2019. Prior to this, Anjeza held various positions at Ironwood Pharmaceuticals from 2012 to 2019, including Senior Director, Strategy and Corporate Performance, and Head of Financial Planning and Analysis. Earlier in her career, Anjeza held other finance positions in the healthcare industry, including at PerkinElmer.
Stéphane Boissel, CEO of SparingVision, commented: “Anjeza’s proven track-record and experience in scaling-up and financing biotech companies will be invaluable to SparingVision as a growing, clinical company. With one gene therapy program in Phase 2, a second soon entering Phase 1, and an ambitious development plan for the whole pipeline, I am delighted to welcome Anjeza, strengthening our management team and preparing for our commercial future.”
Anjeza Gjino, newly appointed CFO of SparingVision, added: “SparingVision is a company with a highly differentiated positioning in the genomic medicines space whose gene-agnostic approach has the potential to provide breakthrough treatments to large, untapped markets like inherited retinal diseases and geographic atrophy. I am thrilled to be joining and be part of such a strong management team, supported by a patient-centric syndicate of investors. I look forward to continuing to support to SparingVision’s mission.”
Anjeza holds an MBA from the Massachusetts Institute of Technology (MIT) and a BS in Corporate Finance from Bentley University. Based in Boston, Anjeza was recognized in 2019 by the Boston Business Journal as an honoree of the “40 under 40”. She is an active member in the MIT Sandbox Innovation Fund Program, mentoring undergraduate, graduate, and Ph.D. student founders through various stages of their start-up process from idea to profitability.
NOTES TO EDITORS
Contacts:
Investors: Nathalie Trepo (nathalie.trepo@sparingvision.com)
Media: ICR Healthcare (sparingvision@icrhealthcare.com)
About SparingVision
SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built a compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs). Both of its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP), a group of IRDs which are a leading cause of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular disease utilizing CRISPR-Cas9 technology.
SparingVision is a spin-off from the Paris Vision Institute and backed by high-quality investors including 4BIO Capital, Adbio Partners, Bpifrance, Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital and Ysios Capital.
Visit www.sparingvision.com for more and follow us on LinkedIn and X @SparingVision